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Over the last decades, the rate of isolation of tubercle bacilli has declined in the developed
countries, while the incidence of infection with nontuberculous mycobacteria (NTM) has in-
creased. In a retrospective study, we analyzed all cases of patients negative for human immunode-
ficiency virus (HIV) and from whom NTM were isolated in the Zurich area of Switzerland from
1983 to 1988. During the 6-year study period, 513 patients infected with NTM were identified,
34 of whom had clinically significant disease. The presentation of mycobacteriosis was found to
be lung disease in 23 cases, soft-tissue disease in 10 cases, and disseminated disease in one case.
The highest attack rate of pulmonary mycobacteriosis was 0.49% and was found in the group of
patients 41-50 years old. During the 6-year period, the incidence of tuberculosis declined from
16.2 to 13.2 per 100,000 population, while the incidence of mycobacteriosis increased from 0.4
to 0.9 per 100,000 population. Clinically nonsignificant NTM isolates were found more fre-
quently in patients with chronic lung diseases (P < .01) and especially in patients with a history of
tuberculosis (P < .001).
The genus Mycobacterium comprises more than 50 differ-
ent species [I]. The two most prevalent species Mycobacte-
rium tuberculosis and Mycobacterium leprae are responsible
for diseases that have threatened humankind in the past and
present. In Western Europe, disease caused by tubercle ba-
cilli has been a diagnostic and therapeutic challenge for gen-
erations of physicians and microbiologists and is regaining
new importance during the ongoing AIDS epidemic. The
diagnosis of leprosy, which is now rare in Western Europe, is
made on the basis of clinical and histopathologic findings,
since M. leprae cannot be cultivated in the routine labora-
tory. In the present study, we focus our attention on the
other species of this genus, the so-called nontuberculous my-
cobacteria (NTM).
Terminology of NTM
A variety of epithets have been proposed for designating
NTM [2, 3]. Anonymous, unclassified, unknown, tuberculoid,
environmental, opportunistic, nyrocin, and MOTT (mycobac-
teria other than tubercle bacilli) have been suggested. Each
of these terms is subject to criticism. The designation atypi-
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cal is still one of the most common, but it is actually a mis-
nomer because these organisms are typical for the genus My-
cobacterium when analyzed microbiologically. In agreement
with the editor of the AmericanReviewofRespiratoryDisease
[4] and the official statement of the American Thoracic Soci-
ety [5], we shall resort to the more neutral term of nontuber-
culousmycobacteria. For disease due to NTM, we propose to
adopt the term mycobacteriosis as used by Runyon [6] and
reemphasized by the editor ofthe AmericanReviewofRespira-
tory Disease [4].This designation would permit a clear differ-
entiation from tuberculosis, the term commonly used for dis-
ease caused by the M. tuberculosis complex (TBC; M.
tuberculosis, Mycobacterium bovis, and Mycobacterium afri-
canum).
Characteristics of NTM
Fundamental differences exist between TBC and NTM.
NTM are ubiquitous in nature, as has been demonstrated in
environmental studies [7-10]. Therefore, it has been possi-
ble to postulate mode and source of infection. Person-to-per-
son transmission of NTM disease generally does not occur
[11]. TBC is, when isolated, always associated with disease.
In contrast, the interpretation of a positive NTM culture is
complicated by the following facts: first, the pathogenic po-
tential of the different species varies greatly; second, coloni-
zation ofan individual without the development of infection
or even invasive disease is possible; and third, a coincidental
isolation ofa NTM species can happen because ofits ubiqui-
tous presence.
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Historical Perspective
The first reports on NTM date back to 1885 [12]. During
the first half of the century, no serious interest was paid to
this group of mycobacteria, although occasional isolates
from clinical specimens were reported [13]. Until recently,
disease caused by TBC has been prevalent [14] to the degree
that only marginal attention was paid to disease due to
NTM [15].
In 1954 Timpe and Runyon [16] were the first to correlate
the known facts about the relationship between human dis-
ease and NTM and provided the first working classification
of these organisms. In 1959 Runyon [17] established an up-
dated classification into four groups, which is valid to this
day and is known as the so-called Runyon classification of
NTM. His classification is based exclusively on phenotypic
characteristics of the various species, such as growth rate and
colonial pigmentation. Within a Runyon group, however,
the various species differ in their clinical relevance. Clinical
interpretation of a positive NTM culture remains unre-
solved, thus calling for reproducible criteria on interpreta-
tion of the clinical relevance of cultured NTM. In 1967 Ya-
mamoto et al. [18] established criteria for distinguishing
disease from colonization and thus provided a diagnostic aid,
which still is valid today. In 1979 Wolinsky [13] reviewed
major aspects ofNTM. He provided a summary of the clini-
cal manifestations, the microbiological properties, and the
historical perspective of NTM.
Over the last decades, the rate of isolation of TBC has
declined in the western hemisphere, while the incidence of
NTM infection has increased [19, 20]. The increase in the
incidence ofAIDS has renewed interest in mycobacteria. Pa-
tients with AIDS are at increased risk of developing a wide
spectrum ofdiseases due to NTM as well as to TBC [21-24].
In Woods and Washington's later review [25], a descrip-
tion of the widened spectrum of clinical manifestations due
to infections with various species in patients who have AIDS
was published. Case reports of infections due to species con-
sidered to be apathogenic and of less common sites of infec-
tion were discussed. A clinical classification based on two
major groups was developed: namely, NTM potentially
pathogenic and rarely pathogenic for humans.
In 1989 another approach to the same problem was put
forth by Davidson [26], in which the mycobacterial species
were correlated with their relative clinical significance.
Correspondingly, a number was assigned to each NTM spe-
cies, ranging from 0 to 10; the higher the number, the greater
the clinical relevance. Furthermore, diagnostic criteria, com-
parable to those set up by Yamamoto et al. [18], were estab-
lished for supporting the diagnosis of disease due to NTM.
Aims of This Study
The main goal of this study was to assess the incidence of
NTM infection and the clinical significance ofNTM isolates
in patients negative for human immunodeficiency virus
(HIV) in Switzerland, on the basis of data collected from
patients in and around Zurich, its most populous city. We
also analyzed the incidence of tuberculosis in the same area
during the same period and the demographic differences be-
tween patients with TBC disease and those with disease due
to NTM. Third, special attention was given to preexisting
clinical conditions of patients from whom NTM had been
isolated as well as to the interpretation of positive NTM cul-
tures by the clinician.
Materials and Methods
Patients
This study is a retrospective analysis of all HIV -negative
patients from whom NTM were isolated in the Department
of Medical Microbiology of the University ofZurich, from 1
January 1983 to 31 December 1988. Only specimens that
were processed in our mycobacteriology laboratory were in-
cluded, not cultures sent to us from other laboratories.
To guarantee a complete and thorough registration ofposi-
tive NTM cultures, we used various methods of data re-
trieval. We systematically checked the laboratory slips for
NTM isolates from the years 1983 and 1984. For the period
between 1985-1988, we were able to extract all specimens
with TBC and NTM isolates with the aid of a computer-as-
sisted data bank. Aside from this data bank, we had used a
record card system in which all isolated mycobacteria were
manually recorded. This system was a valuable control ofall
data analyzed for the entire period of our study. We traced
the submitting institutions (private practices, outpatient clin-
ics, and hospitals) from their orders.
Clinical and Demographic Data: Medical Conditions
To obtain clinical information about our patients, we sent
a questionnaire for clarifying the interpretation of NTM iso-
lates (table 1). If the questionnaire was not returned or was
incomplete, we personally contacted the responsible clini-
cian. In some cases, one of us (M.D.) reviewed the patients'
records. In certain cases we consulted the physician for fol-
low-up ofthe clinical course. When confronted with discrep-
ancies between the clinicians' and our interpretation of the
clinical relevance of a culture positive for NTM, we abided
by the criteria of Yamamoto et al. [18]. Definitions of data
used in descriptive statistics are as follows: ( I ) when the same
species was isolated repeatedly from the same patient, we
counted it only once in the first 12 months of its detection;
(2) when the following events occurred, more than one
NTM isolate was considered or counted for the same patient
-(a) on detection of more than one isolate belonging to
different species in the same 12-month period, (b) on isola-
tion of different species in consecutive years, and (c) on re-
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Table 1. Patient questionnaire for significance ofnon tuberculous
mycobacteria (NTM).
culosis (TB). We, therefore, were able to compare these two
patient cohorts.
NTM Disease and Tuberculosis
Apart from evaluating the epidemiology and clinical rele-
vance ofNTM, we recorded data on all patients with tuber-
Was diagnosis made before receiving the mycobacteriologic result?
What was the final clinical diagnosis?
Was the isolation ofNTM considered clinically significant?
Was chemotherapy initiated because of this result?
peated detection of the same NTM species after an interval
of>2 years; and (3) when the interval between the isolation
ofTBC and NTM was >6 months, we considered the patient
to have a history of tuberculosis.
Laboratory Procedures
Smears of most specimens sent to our laboratory were ex-
amined by the fluorochrome (auramine-rhodamine) proce-
dure [27-29]. Exceptions were gastric aspirates and blood
and urine specimens not submitted by urological clinics or
from patients with a history of urogenital tuberculosis.
Laboratory techniques and methods were consistent dur-
ing the study period except for the pretreatment methodol-
ogy [27-29]. Until 1985 N-acetyl-L-cysteine (3% NaOH,
1.45% sodium citrate, 0.5% N-acetyl-L-cysteine) [27, 28] was
used. In 1986 the modified SDS method, which provided for
a mild and sufficient contamination control [30], was intro-
duced in our laboratory.
Media and procedures used depended on the origin of the
specimen. Specimens from the respiratory tract as well as
other specimens considered not to be sterile (e.g., urine,
feces, gastric aspirates, ejaculate, or endometrial drainage)
were inoculated onto two egg-based Lowenstein-Jensen (L-
J) media (produced in this department), one ofwhich was an
L-J slant and one of which was an L-J slant modified after
Gruft [31]. Incubation time was 8 weeks at 36°C (4 weeks in
5%-10% CO 2 atmosphere and 4 weeks without CO 2) . Growth
was examined visually once a week.
One Middlebrook 7H 11 plate (Difco Laboratories, De-
troit) was inoculated additionally with specimens from pa-
tients with silicosis or who were positive for HIV. Incubation
time was 6 weeks at 36°C with CO 2• These plates were exam-
ined with a dissecting microscope ( 16X magnification) once
a week.
Specimens not considered to be contaminated (CSF, bone
marrow, pleural and pericardial effusions, and lysis-centrifu-
gation blood) were inoculated into two tubes with Middle-
brook 7H9 broth (Difco Laboratories) and onto one Middle-
brook 7H 11 plate. If the smear was positive for AFB, two L-J
slants (one L-J, one L-J modified after Gruft) were also inocu-
lated. After 2 and 4 weeks, respectively, the 7H9 broths were
centrifuged for 15 minutes at 3,300g, and the sediment was
stained for microscopic examination as well as inoculated
onto two L-J slants. All other specimens (e.g., pus, deep
swabs, bladder aspirates, dialysate fluids, and biopsy) were
cultured first on a chocolate agar plate for 24 hours at 36°C
in a 5%-10% CO2 atmosphere. If growth was detected, gram
and Ziehl-Neelsen stains were done. If there was no growth
after 48 hours, the procedure was the same as in the case of
sterile specimens (see above). In case of non-acid-fast
growth, the specimen was treated in the same manner as
specimens from the respiratory tract, except that tissue was
inoculated additionally onto one Middlebrook 7H 11 plate.
Specimens from peripheral sites of the body (e.g., skin,
superficial swabs, and pus) were first inoculated onto a choco-
o
o
o
o
Yes 0 No 0
o
o
o
Yes 0 No 0
Yes 0 No 0
YesDNoD
Yes 0 No 0
YesDNoD
Yes 0 No 0
Positive 0
Negative 0
Not performed 0
YesONoO
Positive 0
Negative 0
Not performed 0
Tuberculin skin test
AIDS
Chronic pulmonary disease
Chronic obstructive pulmonary
disease (COPD)
Bronchiectasis
History of tuberculosis
Others
Malignancy
If yes, what kind of therapy:
Radiotherapy
Chemotherapy
No therapy
Serology for human immunodeficiency
virus (HIV)
Diabetes mellitus
Alcohol abuse
Steroid therapy/immunosuppressive therapy
Congenital immunodeficiency
Connective tissue disease
Was one of the following medical conditions
present at the time the specimen was
collected?
Specimens
We analyzed the number of specimens received per pa-
tient and calculated the percentage of cultures that yielded
NTM. These data were extracted from a list of ~72,000
specimens (~ 12,000 per year) sent to our laboratory for ex-
amination of acid-fast bacilli (AFB). Our laboratory per-
forms this service at no extra cost.
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Number of Isolates
Results
Table 2. Number of patients from whom mycobacteria were iso-
lated, 1983-1988.
Mycobacterium tuberculosis
complex 181 181 168 140 151 150
Nontuberculous mycobacteria 59 94 62 68 103 127
1983 1984 1985 1986 1987 1988
Epidemiological Data on NTM
Of 513 patients with NTM isolates, 34 (7%) had clinically
significant disease. Of 17 different species isolated, only eight
were shown to be clinically significant; thus, the pathogenic
potential of different species varied greatly (table 4). Within
the group of clinically relevant NTMs, the most important
species were Mycobacterium avium complex (MAC), Myco-
bacterium kansasii, Mycobacterium xenopi, and Mycobacte-
rium malmoense. Mycobacterium gordonae was the species
most frequently isolated. Even though it accounted for 45%
ofall isolates, M. gordonae was never shown to be responsi-
ble for disease (table 4).
During the period between 1983 and 1988, a subtotal (ex-
cluding strains isolated in culture of specimens from HIV-
positive patients) of 513 NTM strains were isolated in our
laboratory. Even though the number of specimens examined
remained more or less constant (minimum per year, 11,220;
maximum per year, 14,763; median, 12,768), there has been
an increase of patients with NTM isolates since 1986 (table
2). From 1983 to 1988 the incidence of tuberculosis in Zu-
rich declined from 16.2 to 13.2 per 100,000 population,
which corresponds to an overall decrease of 17%. There were
a total of 971 patients with TB; the number of isolates from
these patients was 1.9 times the number of NTM isolates
during this 6-year study period (table 3).
Pathogen
Identification
Mycobacteria were identified by colonial morphology,
pigment production, growth rate, susceptibility pattern, and
a battery of in vitro tests described in the most updated ver-
sions oflaboratory manuals [27-29, 32].
The Yamamoto criteria [18] that we used in our study are
based on the number ofpositive cultures, number ofcolonies
in a culture, and histopathologic findings. These criteria are,
therefore, applicable to a retrospective evaluation, such as
the present study, in which radiographic findings were only
partly available or radiography was not done at all. In addi-
tion, one extrapulmonary specimen had to be smear and cul-
ture positive or at least two specimens had to be culture posi-
tive. Dissemination was defined as a positive blood specimen
or culture-positive specimens with the same organism from
two different body sites.
Determination of Clinical Significance
Attack Rate
late agar plate and incubated up to 48 hours at 36°C, in a
5%-10% CO2 atmosphere. In case of non-acid-fast growth,
the specimen was decontaminated, and two L-1 slants each
were inoculated and incubated at 30°C and 36°C. Further,
two L-1 slants supplemented with ferric ammonium citrate
were incubated at 30°C. Ifthere was no growth on the choco-
late agar plate, one L-1 slant supplemented with ferric ammo-
nium citrate and six tubes with Middlebrook 7H9 broth were
inoculated. Three of the tubes and the L-1 slant were incu-
bated at 30°C. The remaining three tubes were processed as
in the case of a noncontaminated specimen (described
above). When the direct smear was positive, L-1 slants were
inoculated first.
We analyzed all respiratory tract specimens obtained from
'1986 to 1988 and determined the age-specific attack rate.
Exclusions
We excluded all HIV-positive patients from our study.
The following cases were also excluded from our evaluation:
five cases in which the Mycobacterium scrofulaceum isolates
were submitted by a physician whose bronchoscope had
been contaminated by the above-mentioned mycobacte-
rium, one case in which the culture was contaminated, and
one case in which the medium had to be decontaminated
several times before isolation.
Demographic Data
The sex distribution differed between the group with clini-
cally significant and the group with nonsignificant NTM iso-
lates. Sixty percent of the group infected with nonsignificant
isolates were male. The number of male and female patients
with mycobacteriosis was the same. The median age of pa-
tients with nonsignificant isolates was 65 years. Among pa-
tients with any type of mycobacteriosis, the median age was
52 years. The number ofpatients with pulmonary mycobac-
teriosis found per age group who were screened for AFB is
shown in figure 1. The mean attack rate was 0.12% (SD ±
0.15). The highest rate occurred in the group aged 41-50
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Table 3. Incidence of mycobacterial diseases in the Zuricharea, 1983-1988.
Incidence of Incidence of
Population of mycobacteriosis tuberculosis
Zurich area No. of cases of (per 100,000 No. of cases (per 100,000
Year (in millions) mycobacteriosis population) of tuberculosis population)
1983 1.119 4 0.4 181 16.2
1984 1.120 3 0.3 181 16.2
1985 1.123 4 0.4 168 15.0
1986 1.128 7 0.6 140 12.4
1987 1.133 6 0.5 151 13.3
1988 1.140 10 0.9 ISO 13.2
years. The age distribution of patients with TB showed a
bimodal distribution as was expected: one peak occurred in
the group aged 21-30 years and the other in the group aged
71-80 years (data not shown).
Localization of Disease
The presentation of mycobacteriosis was found to be lung
disease in 23 cases (68%), disseminated disease in one (3%),
and soft-tissue disease in 10 (29%) (figure 2). There were
more cases of lung mycobacterioses in the second halfof the
study period: five smear-positive and two smear-negative
cases in the first half; nine smear-positive and seven smear-
negative cases in the second half.
Lung disease. Pulmonary mycobacteriosis was caused by
M. kansasii in eight patients and by MAC in eight patients.
Table 4. Pathogenic potential of nontuberculous mycobacterial
isolates (n = 513).
In the remaining cases, we found M. xenopi (four patients),
M. malmoense (two patients), and Mycobacterium simiae
(one patient).
Disseminated disease. Only one case showed generalized
disease due to MAC.
Soft-tissue disease. Three of 10 cases of soft-tissue infec-
tion occurred in children with cervical lymphadenitis. These
cases were caused exclusively by MAC. Two of these chil-
dren had positive skin tests for M. avium (purified protein
derivative test [PPD-A; Statens Serum Institute, Copenha-
gen]; skin testing for NTM antigens is not a common routine
procedure in the Zurich area). In five of the 10 cases of soft-
tissue infections, the following species were detected: Myco-
bacterium terrae (one, ulcer), Mycobacteriumfortuitum (two,
abscesses), MAC (four, cervical lymphadenitis), and M. kan-
sasii (one, abscess). One case of swimming pool granuloma
caused by Mycobacterium marinum was found in a young
woman, and an additional case ofa tenosynovitis due to M.
malmoense was found in an elderly man. The number of
cases of soft-tissue infections remained constant during the
study period.
* Three rapidly growing, two scotochromogenic, and one nonphotochro-
mogenic species.
Isolate
M. avium complex
M. kansasii
M. xenopi
M. malmoense
M. fortuitum
M. simiae
M. marinum
M. terrae
M. gordonae
M. scrofulaceum
M. nonchromogenicum
M. chelonae
M. f1avescens
M. triviale
M. gastri
M. thermoresistibile
M. vaccae
Others*
No. of strains associated with disease/
total no. of strains (%)
13/61 (21)
9/35 (26)
4/25 (16)
3/3 (100)
2/36 (6)
1/1 (100)
1/3 (33)
1/31 (3)
0/229
0/22
0/16
0/14
0/13
0/8
0/6
0/2
0/2
0/6
Medical Conditions
Table 5 shows associated medical conditions for patients
infected with NTM isolates. There was no predominant un-
derlying disease in the group of patients with mycobacterio-
sis compared with the group of patients with nonsignificant
isolates (table 5). Clinically nonsignificant NTM isolates
were found more frequently in patients with chronic lung
diseases (P < .0 I) and especially in patients with a history of
TB (P < .00 I) than were significant isolates.
Immunosuppression
Of 513 patients with NTM isolates, we identified 49 re-
ceiving immunosuppressive therapy, of whom only two had
disease due to NTM. The causative species in a patient who
had non-Hodgkin's lymphoma and who was receiving che-
motherapy was MAC. The other patient who had chronic
obstructive pulmonary disease (COPD) and who was receiv-
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Figure 1. Age-dependent frequency of
patients from whom respiratory tract speci-
men s were submitted between 1986-1988
and of patients with pulmonary mycobac-
teriosis. (. = includes one Hlv-positive pa-
tient) .
ing steroids also had pulmonary mycobacteriosis due to M.
xenopi.
Therapy
Antituberculous drug therapy was initiated in 22 (65 %)of
all cases caused by clinically relevant NTM and in 42 (9%)of
all cases cau sed by nonsignificant isolates. In three of the 10
cases of soft-tissue infections. surgical treatment was com-
bined with antituberculous drugs.
Interpretation of Results by Physicians
When evaluating a positive NTM culture and estimating
the clinical relevance of this result according to the Yama-
moto criteria [18], we observed an increasing conformity
with the clinician's judgment over the study period. In 1983-
1984, only 30% of patients with NTM isolates considered
relevant by the responsible physician were actually signifi-
cant; in 1985-1986, 53%; and in 1987-1988. 86%.
Specimens Examined for AFB
One hundred sixty-six spec imen s from 34 patients with
mycobacteriosis were received (4.9 specimens per patient),
whereas 1,911 specimens from 479 patients with nonsignifi-
cant NTM isolates were received (4 .0 specimens per pa-
tient). The rate of positive cultures per submitted specimens
was different for patients with mycobacteriosis and those
with casual NTM isolates. On ly one of 3.7 submitted speci-
mens was positive among the patients with nonsignificant
NTM isolates. Conversely. one of 1.9 submitted specimens
was positive among patients with mycobacteriosis.
Microscopy
Four hundred forty-seven patients were found to have one
or more positive smears from 1983 to 1988. In 424 patients
(95%) TBC was the cau sative organism, in 15 patients (3%)
NTM was found to be respon sible for disease. and in eight
patients (2%) a non significant NTM isolate was identified.
Fifteen (44%) of 34 patients with mycobacteriosis had smear-
positive specimens. In the group of pat ients with non signifi-
cant isolates. only eight (2%) had a positive smear. Six of
these eight patients were found to have chronic lung disease.
including four patients with a history of tuberculosis. one
with COPD. and one with bronchiectasis. One patient with
previous and concurrent tuberculosis had a positive smear of
a specimen from which M. gordonaewas isolated. One of the
remaining two patients was being treated for a prostate gland
carcinoma, and one was found to have a Zenker's diverticu-
lum. When analyzing the site of origin of specimens positive
on microscopic evaluation . we found that all originated from
the respiratory tract.
For 905 patients with pulmonary or extrapulmonary tu-
berculosis, one or more smears were performed. Smears for
424 (47%) of these pat ients showed AFB. Ninety percent of
these microscopically positive specimens originated from the
respiratory tract (1 .160 of a total of 1,292 specimens).
Discussion
Among all mycobacteria. TBC remains the most impor-
tant species that causes disease [14. 15. 19. 33]. As in other
countries of the western world , a downward trend in the inci-
dence ofTBC disease had been observed in Switzerland over
the past decades. In 1990 Rieder et al. [34] demonstrated in
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Figure 2. Sites of mycobacteriosis and patients recorded for each year from 1983 to 1988. Y axis = number of patients.
a Swisssurvey a decline in the incidence ofTBC disease from
108.1 cases per 100.000 inhabitants in 1945 to 17.4 cases
per 100,000 inhabitants in 1988. A progressive increase in
the number ofNTM isolated at our laboratory was observed
for approximately the last 10 years. In 1977 Nykanen [35]
found that 2.2% of all cultures positive for AFB contained
NTM; however, the technique at that time was not as good as
it was in 1981. In 1981 NTM were found in 17% of all pa-
tients with mycobacterial isolates in the tuberculosis labora-
tory [36]. The present study shows an extension of this trend
in terms of total NTM strains isolated as well as of clinically
significant NTM isolates.
Geographic Differences
Geographic differences in the pattern of NTM species
have been demonstrated in various studies. In 1969 Edwards
et al. [37] found the highest reactivity to antigens prepared
from M. intracellulare (PPD-B) and M. scrojulaceum (PPD-
G) in the southeastern United States. Correspondingly, the
frequency of recovery of isolates of these and the related
species M. avium was also highest in that area [37]. Environ-
mental studies [7] showed that these species are found in
waters and soils of the Southeast rather than of the North-
east.
Comparing investigations from Europe, we found a differ-
ent frequency in the isolation of species. In an extensive
study over 22 years (1965-1986) from the eastern part of
Germany [38], M. intracellulare was the species most fre-
quently isolated from humans in the group of potentially
pathogenic NTM. It was followed in order ofdecreasing fre-
quency by M. kansasii, M. xenopi, M. fortuitum, M. avium,
Mycobacterium chelonae, and M. scrofulaceum. M. marinum
was isolated only from animals during the study period. In
the group ofNTM rarely considered as pathogens, M. terrae
was found most frequently, followed by a group of sco-
tochromogenic species (e.g., M. gordonae).
A bacteriologic survey from Sweden [39] between 1973
and 1981 showed MAC to be the species isolated most fre-
quently. M. xenopiwas found to be second, followed in order
ofdecreasing frequency by M. kansasii, M. marinum, Myco-
bacterium szulgai. and a group of rapid growers. In another
Swedish study [40] non-BCG-vaccinated schoolchildren un-
derwent skin tests. For -90% of the children, the sensitin
reaction to M. scrofulaceum or to M. aviumwas larger than or
equal to the tuberculin reaction. An environmental study
from Wales (United Kingdom) disclosed an increase in the
incidence of mycobacteriosis due to M. kansasii from 1953
to 1970; during the first 6 years of the study period there
were 25 cases, the second 38 cases, and the third 52 cases
[41]. The natural source ofthis microorganism, the most fre-
quently isolated NTM species in this area, was not found.
Other NTM species found less often than M. kansasii were
M. intracellulare and M. avium.
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Table5. Medical conditions associated with isolation of nontuberculous mycobacteria.
No. (%) of isolates
Clinically Clinically
significant nonsignificant Total
Medical condition (n 34) (n == 479) (n==513)
Chronic lung diseases 15 (44) 241 (50)* 256
Chronic obstructive pulmonary disease
(COPD) 12 (35) 143 (30) 155
Bronchiectasis 2 (6) 19 (4) 21
History of tuberculosis I (3) 126 (26)t 127
Concurrent tuberculosis 2 (6) 19 (4) 21
Others 3 (9) 25 (5) 28
Malignancy 3 (9) 76(16) 79
Radiotherapy 1 (3) 8 (2) 9
Chemotherapy 1 (3) 12 (3) 13
Surgery 0 21 (4) 21
None I (3) 5 (1) 6
Missing data 1 (3) 9 (2) 10
Tuberculin skin test
Positive 8 (23) 64 (13) 72
Negative 5 (15) 47 (10) 52
Diabetes mellitus 5 (15) 36 (8) 41
Alcohol abuse 6 (18) 62 (13) 68
Immunosuppressive therapy 3 (9) 46 (10) 49
Connective tissue disease 2 (6) 15 (3) 17
* P< .01.
t P< .001
A study from Ontario, Canada [42] showed an increasing
number of cases of mycobacteriosis due to M. xenopi from
1975 to 1985, now the second most commonly isolated
NTM after MAC. In a report from northern India [43], 8% of
patients with mycobacterial species harbored NTM isolates,
mostly M. fortuitum (endometrial biopsy, five; sputum,
three; CSF, two; bronchial washing, skin biopsy, and lymph
node aspirate, one each). A similar result was found in a
study from Jeddah, Saudi Arabia [44]: of the NTM isolates
from 9%of patients, more than half belonged to the rapidly
growing mycobacteria M. fortuitum (pulmonary specimen,
nine; urogenital, 10; miliary, one; soft-tissue, one), M. che-
lonae (pulmonary specimen, four; urogenital, two; CSF,
one), and Mycobacterium smegmatis (pulmonary specimen,
three; urogenital, one). In the last two studies sputum speci-
mens were decontaminated by the N-acetyl-L-cysteine/
sodium hydroxide method.
Isolation of NTM from Healthy Persons
In the I950s increasingly frequent reports of NTM asso-
ciated with pulmonary disease [ I7] and in asymptomatic pa-
tients [45] prompted a study by Edwards and Palmer [46] to
check for NTM in 122 apparently healthy persons ofa small
rural community in southwestern Georgia. Some ofthe speci-
mens appeared to be sputum, but many of them were just
saliva. After decontamination the sediment was inoculated
onto one slant of an egg-based medium. Growth was de-
tected in cultures of30 specimens: Nocardia species from 12,
Streptomyces species from two, scotochromogenic NTM
from four, nonphotochromogenic NTM from eight (seven of
them MAC), and rapid growers from five (three of them M.
fortuitum). There were two mixed cultures, and one culture
was lost. Chest roentgenograms for 29 persons with positive
cultures were unremarkable. Edwards and Palmer concluded
that the gastrointestinal tract may have been a frequent por-
tal of entry for natural infection with some of the NTM.
In the early 1970s, the ratio of NTM to M. tuberculosis
isolated in the mycobacteriology laboratory of the Hospital
of the University of Pennsylvania was 3:2. A study [47] was
therefore undertaken for determining if the oral cavity con-
tributed to these large numbers of clinically insignificant
NTM in sputum during collection. Each patient first used 20
mL of Todd-Hewitt broth as a mouth rinse without gargling
and expectorated the fluid. Then the patient produced in-
duced sputum by repeatedly inhaling a warmed aqueous so-
lution consisting of 10% NaCl and 15% propylene glycol.
From 19 (17%) of 113 patients attending the outpatient
clinic, 32 NTM isolates were obtained. Examination of the
data indicated that 24 of 32 organisms were isolated from
cultures ofeither mouthwash or sputum. The following num-
bers of species were detected in the indicated numbers of
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patients: MAC, 9 (9 patients); Mycobacterium phlei.8 (3); M.
scrofulaceum, 6 (5); M. kansasii, 5 (3); M. smegmatis, 3 (I);
and M. terrae. I (I). Since two-thirds of these NTM were not
found in paired specimens but were distributed about
equally in mouthwashes and sputa, the author concluded
that their presence was random and their acquisition may
have been by ingestion.
Almost 15 years later, an editorial written about the high
proportion ofMAC infections in patients with AIDS by Col-
lins [48] prompted another important study. Portaels and
co-workers [49] examined the mycobacterial flora of the
stools of 50 healthy European volunteers. After decontami-
nation the pellet was inoculated onto four slants of Ogawa
egg yolk medium and incubated at 30°C for 6 months. Cul-
tures of26 specimens were positive for NTM. The number of
colonies varied between one and three per slant. Cultures of
six specimens failed to yield growth in subcultures. From the
20 remaining positive specimens, 26 different strains were
detected: M. simiae (14), MAC (5), M. gordonae (5), and M.
malmoense (2). Six cultures revealed two different species.
The finding ofM. simiae and M. malmoense, both recognized
as causes of human diseases. was particularly noteworthy.
Diagnostic Criteria for Mycobacteriosis
In the absence of specific diagnostic features, isolation of
NTM in culture is essential for diagnosis. However, as these
organisms are commonly found in nature, a single positive
sputum culture is not sufficient for diagnosis of mycobacter-
iosis.
In 1990 the American Thoracic Society put forth the first
official statement on diagnostic and therapeutic standards
for pulmonary disease due to NTM [5]. There are different
criteria for patients with cavitary lung disease, for patients
with noncavitary lung disease, and for patients with cavitary
or noncavitary lung disease for whom the sputum evaluation
is "nondiagnostic or [for whom] another disease cannot be
excluded." Additionally, failure to clear the organism after a
course ofbronchial hygiene supports the diagnosis ofpulmo-
nary mycobacteriosis. An investigation of 492 patients with
pulmonary disease caused by M. kansasii and M. intracellu-
lare by Ahn et al. in 1982 [50] demonstrated that criteria
based on the presence or absence of cavitation and on the
duration of sputum positivity after initiation of therapy en-
abled a more accurate distinction ofcolonization from inva-
sive disease.
A localized soft-tissue lesion is a relatively uncommon
form of mycobacteriosis. Cases of mycobacteriosis involving
skin, soft tissue, tendon sheaths. joints, and bones have been
reported previously [13]. The role ofNTM in granulomatous
synovitis was described by Sutker et al. [51] in 1979. To
evaluate the significance of NTM in this localization, the
authors used the following features: (1) general clinical fea-
tures were reasonably characteristic; (2) many of the lesions
were closed lesions, i.e., not open to surface contamination;
and (3) many of the tissue sections showed granulomas con-
taining AFB. In their study, NTM ofthe Runyon groups I, II,
and III were very rarely isolated from surface lesions as "con-
taminants."
Attack Rate
There are no data published about attack rates in cases of
pulmonary mycobacteriosis. In our study we found the high-
est rate of 0.49% in the group of patients 41-50 years old.
Incidence of Mycobacteriosis
In a comparison of studies from different countries on the
incidence ofmycobacteriosis and the species involved, a high
degree of conformity can be found. In a survey from the
Centers for Disease Control (CDC) in the United States (At-
lanta, GA) [11, 52] from 1981 to 1983, the estimated preva-
lence of mycobacteriosis in the United States was 1.8 per
100,000 population. A study in Japan [53] from 1981 to
1984 showed an incidence of pulmonary mycobacteriosis of
1.73 cases per 100,000 population. In 1988 we observed 0.9
cases of mycobacteriosis per 100,000 population in the can-
ton ofZurich. Considering the fact that we excluded all HIV-
positive patients, these data are remarkably similar, even
though different diagnostic criteria for defining mycobacter-
iosis were used in these three studies.
Despite certain geographic differences [52-55], MAC and
M. kansasii represent the two clinically most important spe-
cies of NTM. In the study from the CDC [52], 62% of the
cases ofmycobacteriosis were associated with MAC and 24%
with M. kansasii. In Japan from 1983 to 1984, MAC was
identified in '"70% of the patients with mycobacteriosis and
M. kansasii in 25%. We found MAC in 13 (38%) of 34 pa-
tients and M. kansasii in nine patients (26%) to be responsi-
ble for disease. M. gordonae, the most frequently isolated
species, was never shown to be responsible for disease. This
species has been found in tap water in different parts of the
world [56, 57]. We assume that transient colonization of a
host is frequent, and therefore the overall chance ofisolation
is very high. Different NTM species have been observed as
colonizing water systems, as described by Lockwood et al.
[58] who registered an outbreak ofM. terraein clinical speci-
mens associated with a hospital's potable water supply in
1986. The concentration of potentially pathogenic NTM
(like MAC) in hospital water supplies is ofinterest as a possi-
ble source of infection for immunocompromised patients.
Corresponding environmental studies have been provided
by Du Moulin and co-workers in 1988 [59].
Obtaining specimens from the respiratory tract by fiberop-
tic bronchoscopy is a common procedure. A well-known
problem is the possibility of cross-contamination of speci-
mens by the bronchoscope, since in the process of steriliza-
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tion ofthis instrument several possible sources ofcontamina-
tion may be involved. Therefore, it is not surprising that sev-
eral reports on mycobacterial cross-contamination by NTM
have been described [60-64].
Site of Mycobacteriosis
Lung disease. In our study, mycobacteriosis was local-
ized exclusively in the respiratory tract of two-thirds of the
patients. There were more cases oflung mycobacteriosis dur-
ing the second half of the study period. During the first half
of the study period, two of seven cases were smear negative
vs. seven of 16 in the second half. Although we had changed
our decontamination procedure, we do not believe that this
change was responsible for the slight increase. The majority
of the cases were smear positive and most probably occurred
independently of the decontamination procedure.
In this group, M. kansasiiwas found to be responsible for
eight of23 cases. As described by Raleigh in 1988 [65], pul-
monary localization is the most common manifestation of
disease due to this species, even though various other clinical
presentations have been reported [65, 66]. Clinical features
and course ofpulmonary mycobacteriosis due to M. kansasii
were investigated in 1969 by Johanson and Nicholson [67].
This study demonstrated that patients with previously
healthy lungs responded remarkably well to treatment, even
though the extent of mycobacteriosis did not differ from that
in patients with underlying pulmonary disease. A similar ex-
perience was reported by Lillo et al. in 1990 [68] who inves-
tigated 47 cases of pulmonary and eight of disseminated M.
kansasii disease. For 5 years a systematic review was con-
ducted ofclinical, microbiological, and radiographic data on
M. kansasiidisease assembled from the records of72 patients
[69]. Twenty-three patients (32%) were found to be coin-
fected with HIV. This dual infection had increased from 0 to
58%over the study period. Twenty-two of the 23 dually in-
fected patients had M. kansasii isolated from the respiratory
tract. With use ofcriteria as defined by Ahn et al. [50], only
five patients had persistently positive sputum or bronchial
washings (suggesting mycobacteriosis) without colonization
of the respiratory tract. An increase in the incidence of lung
disease due to M. kansasii has been reported from different
countries of the world [41, 70, 71]. During our study period,
such an increase in incidence of mycobacteriosis due to M.
kansasii was not observed.
MAC was found as the causative agent in eight of our
patients with pulmonary mycobacteriosis. Seven of these pa-
tients were considered immunocompetent, and one patient
was receiving immunosuppressive therapy for the treatment
ofnon-Hodgkin's lymphoma. Increasing numbers ofpulmo-
nary disease due to MAC in immunocompetent patients
have been reported [39, 72]. Predisposing medical condi-
tions observed in these patients were chronic pulmonary dis-
eases such as COPD, bronchiectasis, previous tuberculosis,
pneumoconiosis, or bronchogenic carcinoma [13].
Four patients in our study were found to have pulmonary
mycobacteriosis due to M. xenopi. Three of them were men,
and the ages ranged from 54 to 74 years. M. xenopihas been
detected with different frequencies in different geographic
areas. The first reports came mainly from Europe. In coastal
regions of England, the isolation of M. xenopiwas reported
frequently, with many of these isolates interpreted as clini-
cally significant [73]. A detailed bacteriologic study of this
species, including case reports from Denmark, was published
by Engbaek et al. in 1967 [74]. Colonization of water sys-
tems by M. xenopi was soon recognized as a possible source
of contamination or even infection [75]. Smith and Citron
[76), at Brompton Hospital in London, isolated M. xenopi
from the sputum of 23 patients in a 6-year period; these iso-
lates represented 56%ofall NTM isolated at Brompton Hos-
pital. In 15 of these patients, pulmonary disease due to this
organism was suspected. Banks et al. [77] reviewed treat-
ment and response in patients with pulmonary mycobacter-
iosis due to M. xenopi in 1984. Of the 47 patients, 39 (83%)
were men, and the mean age of the group was 61.5 years
(range, 36-84 years). Preexisting lung disease was present in
35 cases (74%), of which healed TBC disease accounted for
14, chronic bronchitis and emphysema for 12, and bron-
chiectasis for three; whereas three other patients had intersti-
tial pulmonary fibrosis. In the Canadian province ofOntario,
M. xenopi is a relatively common NTM isolate, and numer-
ous cases of disease due to this species have been observed
[42, 78, 79). Until now, reports ofM. xenopicases from the
United States have remained rather rare [52]. One of our
patients affected by M. xenopiwas receiving immunosuppres-
sive therapy. A comparable case of pulmonary disease due
to this species in a renal allograft recipient receiving im-
munosuppressive therapy was reported by Weber et al. in
1989 [80].
Two ofour patients had evidence ofpulmonary mycobac-
teriosis caused by M. malmoense. Both patients did not have
pulmonary symptoms, and cavitary lesions were found by
chance. M. malmoense was described and named by
Schroder and Juhlin in 1977 [81]. This species was observed
predominantly in northern Europe. Over the last years, an
increasing number of isolates were reported from England
[82-84], Scotland [85], and the Scandinavian countries [86].
Pulmonary mycobacteriosis represents the main manifesta-
tion of M. malmoense infection and is similar to pulmonary
tuberculosis. Cavitary lesions are observed frequently [85].
There was one patient in our series who had pulmonary
disease due to M. simiae. Results of biochemical tests were
most likely compatible with M. scrofulaceum, which was con-
firmed by the reference laboratory in Borstel, Germany. The
isolate was considered not to be clinically significant at that
time. Retrospectively, it seems possible that this strain iso-
lated in 1985 was M. simiae. Confusion of M. simiae with
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MAC or with M. scrofulaceum may occur [87] because of
similar biochemical properties as well as colonial morphol-
ogy. In 1975 the first case of human mycobacteriosis due to
M. simiae was reported by Krasnow and Gross [88]. The
patient was an elderly woman with chronic cavitary lung
disease and numerous positive sputum cultures. In the mean-
time, additional cases of pulmonary [89, 90] and even dis-
seminated [90] disease due to M. simiae have been described.
In 1989 Krummel et al. [91] reported the first three pulmo-
nary manifestations ofdisease due to this species observed in
Europe. The source of this rarely isolated organism remains
unclear.
Disseminated mycobacteriosis. In only one case ofan 82-
year-old man with pulmonary disease due to MAC was the
same species isolated from both urine and sputum. This gen-
eralized form ofdisease is very rare in the immunocompetent
host [13, 92]. In 1985 Horsburgh et al. [93] reported 13 cases
with disseminated MAC infection.
Cervicallymphadenitis. MAC wasalso the species respon-
sible for three of our cases of cervical lymphadenitis in chil-
dren and in one case ofa 59-year-old woman. First reports of
NTM associated with this localization date back to the
1950s. In 1956 Prissick and Masson [94] found a scotochro-
mogenic NTM species in 25 children with cervicallympha-
denitis and proposed the name M. scrofulaceum. As reviewed
by Lincoln and Gilbert [95], NTM was responsible for super-
ficiallymphadenitis in children in an increasing number of
cases. In 1963 a study from the Cleveland area [96] showed
M. scrofulaceum to be the responsible agent in 35 of 43 chil-
dren with cervical adenitis. In the remaining patients, MAC
was found in six and M. kansasii and M. fortuitum in one
each. Recent reports showed a preponderance of MAC in
this localization [97-100]. Possible geographic differences or
a changing pattern of infective agents has been proposed as
explanations for these findings [98). In contrast, in adults
with cervical lymphadenitis TBC is still the most important
causative agent, as reported by Huhti et al. in 1975 [101] and
Levin-Epstein and Lucente in 1982 [102].
Skin and soft-tissue infections. Street et al. [103] reviewed
the records of patients with NTM infections of the skin who
were seen between 1963-1988 at the Mayo Clinic in Roches-
ter, Minnesota. Only culture-positive cases were included.
Fourteen patients were identified, and the following species
were found: M. marinum (seven patients), MAC (three), M.
kansasii, M. chelonae, M. fortuitum, and Mycobacterium ul-
cerans (one each). M. ulcerans infection occurred in a 5-year-
old boy from Nigeria.
In our series, M. marinum was isolated from a swimming
pool granuloma localized at the elbow of a 26-year-old
woman. The patient was known to visit public indoor swim-
ming pools frequently. M. marinum is the NTM species most
commonly responsible for this kind of soft-tissue infection,
which is also known by the name of "fish tank granuloma"
[13, 104]. An outbreak of 80 cases of granulomatous skin
lesions acquired in a swimming pool in Sweden was de-
scribed by Linell and Norden in 1954 [105]. The lesions
were observed mostly on the elbows. The causative NTM
species isolated from the soft-tissue lesion of these patients
was named "Mycobacterium balnei," later shown to be synon-
ymous with M. marinum. A similar outbreak affecting more
than 290 people in Colorado was reported by Mollohan and
Romer in 1961 [106]. These people acquired the infection
when they swam in a public pool of warm mineral water
contaminated by M. marinum.
A 74-year-old man of our series developed tenosynovitis
of the wrist months after decompression of the median nerve
in the carpal tunnel. Reoperation was necessary. Macroscopi-
cally, a shaggy tenosynovitis with numerous "rice bodies"
was found. The surgeon, who was experienced with the clini-
cal appearance oftuberculous tenosynovitis, suspected myco-
bacterial infection. Tissue samples yielded a nonphotochro-
mogenic NTM, M. malmoense. This species was first
described in 1977 [81]. However, similar strains had already
been isolated in 1954 [107]. The patterns observed on liquid
chromatography were distinctive and supported recognition
of the group as an entity named "provisional new species 2."
In 1976 the original strains from Malmo, Sweden, and from
Wales were compared and turned out to be identical [84]. In
1988 Prince et al. [108] published the first case ofa M. mal-
moense infection of the hand that presented as carpal tunnel
syndrome. There are a number of similarities between this
case and ours. Both patients were in an older age group.
Localization and clinical presentation were similar. NTM in-
fections of the hand have been reported previously [39, 97,
109). The species responsible for most of these cases was M.
marinum [8, 110). Less frequently found were M. kansasii
[111], MAC [112], M. terrae [113], M. fortuitum [114], M.
chelonae [115], and M. szulgai [116].
We observed cutaneous disease due to M.fortuitum in two
patients. One of them was a 45-year-old woman who had a
history of repeated injections for the treatment of rheumatic
disease. She developed an abscess at the site of these injec-
tions and was treated by surgical debridement. The second
case was seen in a 41-year-old man in whom the route of
infection was not known. It is likely that he presented with a
community-acquired form of disease. M. fortuitum belongs
to the rapidly growing mycobacteria, a group that is most
commonly involved in soft-tissue infections [13, 25]. Infec-
tions due to both M. fortuitum and M. chelonae (M. fortuitum
complex) are generally associated with a penetrating injury
of the skin [117]. Soft-tissue and wound infections are the
common clinical manifestation of disease due to the M. for-
tuitum complex [118]. Reports ofpulmonary mycobacterio-
sis due to M. fortuitum demonstrate that this form ofdisease
does exist [119, 120).
In our series, M. terrae was detected both microscopically
and in culture of specimens of a superficial, granulomatous,
partly ulcerating lesion on the forearm ofa 50-year-old man.
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Only few cases ofdisease due to M. terraehave been reported
(septic arthritis and synovitis [121, 122]).
From the last of our 10 patients with soft-tissue diseases,
M. kansasii was cultured from pus. The 78-year-old woman
suffered from an abscess in the psoas region and had no his-
tory of trauma. The patient was immunocompetent. Cutane-
ous lesions have been seen occasionally in this disease [103,
123, 124].
Other Mycobacterial Species with a Pathogenic Potential
M. szulgai. M. szulgai was first recognized in 1972 [125]
and superficially resembled M. gordonae. The distinct char-
acteristic of this species is pigment production: when grown
at 37°C, the organism is scotochromogenic; when grown at
room temperature, the colonies are photochromogenic. Ma-
loney et al. [126] published three cases of infection with M.
szulgai and reviewed 24 previous cases reported before 1987.
Most of the cases were of chronic pulmonary disease with
chest roentgenograms commonly showing cavitary lesions.
Other presentations included olecranon bursitis, tenosynovi-
tis [116], other soft-tissue infections, and localized cutane-
ous disease [126].
M. ulcerans. This organism was first isolated in 1948
from a child who had chronic skin ulcers in Australia [127].
Most cases have been seen in Africa, Malaysia, and other
countries with tropical or temperate climates. M. ulcerans
grows very slowly even at its optimal temperature of 30°C-
33°C. Up to 12 weeks may be required for colonies to de-
velop, which tend to resemble those of tubercle bacilli. This
is also the only species in the genus for which production ofa
soluble toxin has been proved [128]. Recently, Hayman and
McQueen [129] reviewed the pathology of cutaneous ulcers
resulting from M. ulcerans.
Mycobacteriumhaemophilum. This organism grows opti-
mally at temperatures <37°C and is unique in requiring he-
moglobin or hemin for growth. M. haemophilum was first
recovered in 1978 in Israel from the subcutaneous lesion ofa
patient with Hodgkin's disease [130]. Later, cases were re-
ported of patients receiving immunosuppressive therapy for
kidney allografts [131] or patients with AIDS suffering from
tenosynovitis [132]; however, there are also reports of M.
haemophilum causing cervical lymphadenitis in otherwise
healthy children [133, 134].
Mycobacteriumasiaticum. In a routine diagnostic labora-
tory, M. asiaticum may be misidentified as M. gordonae.
There is only one easily determined attribute: M. gordonae is
scotochromogenic and M. asiaticum is photochromogenic.
M. asiaticum was first described by Weiszfeiler et al. in 1971
[135]. So far, only a few cases ofpulmonary mycobacteriosis
due to this species have been reported [136].
M. smegmatis. M. smegmatis is traditionally regarded as
a frequent contaminant of the lower end of the urethra, but
in fact it is more commonly cited in medical textbooks than
it is isolated from clinical specimens. Collins et al. [137] en-
countered it less than a dozen times among some 5,000
NTM isolates examined in 10 years. In 1986 Vonmoos et al.
[138] reported the first case of pleuropulmonary disease
caused by M. smegmatis. Wallace and co-workers [139] iden-
tified 22 additional human isolates of M. smegmatis from
Australia and the southern United States: 19 were from skin
or soft-tissue infections, and none were from urine or the
male genital tract.
Mycobacterium shimoidei. The original description of
this species was published in 1975 by Tsukamura et al [140].
The acid phosphatase distinguishes M. shimoidei (positive)
from the closely related M. malmoense (negative). Clinically
significant isolates from the respiratory tract were reported
from Japan [140] and from Germany [141].
Mycobacterium genavense. Recently, Hirschel et al.
[142] reported a case of a patient who was seropositive for
HIV and whose disease clinically resembled infection with
MAC. Numerous acid-fast rods were found in nearly all tis-
sues examined, but the cultures remained negative. In a sub-
sequent publication from the same group, a second similar
case was identified [143]. Ribosomal RNA (rRNA) se-
quences of isolates extracted from infected tissues of patient
1 contained conserved sequences common to all mycobac-
teria. While other parts of the sequences differed from those
of all known mycobacteria, they were identical to the rRNA
sequences ofan isolate from a second specimen from patient
2. For this previously unknown species they proposed the
name M. genavense [143]. Additionally, Nadal et al. [144]
reported three cases in pediatric patients with AIDS.
Species of Mycobacteria Generally Considered
To Be Nonpathogenic
A few species, such as M. gordonae, Mycobacterium
nonchromogenicum. Mycobacterium triviale, Mycobacterium
gastri, and almost all rapidly growing mycobacteria (M. for-
tuitum and M. chelonaeexcluded) are rarely associated with
human disease [13, 25, 145].
Medical Conditions
In our study we explored predisposing medical conditions
similar to those observed in former studies on NTM. When
comparing patients who were infected with nonsignificant
isolates with those affected by mycobacteriosis, we found sim-
ilar occurrences of underlying diseases (table 5). A possible
explanation is that these predisposing factors also facilitate
the colonization of a patient. More than one-fourth of the
patients infected with nonsignificant NTM isolates were
found to have a history oftuberculosis. Possible explanations
for this observation may be the colonization of preformed
cavities by NTM or the mere fact that former TB patients are
screened for AFB more frequently [146]. The chance of iso-
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lating an ubiquitous organism is therefore much higher. In
contrast with TB patients, for whom the young age group was
found to be predominantly foreign (non-Swiss) and the older
age group of Swiss nationality [34], no preferential ethnic
group could be determined in the group with NTM. This
finding can be explained by the different mode and sources
of infection in TB and disease due to NTM, respectively.
Transmission of TB is facilitated by crowded housing. In
contrast, person-to-person transmission of NTM disease
through aerosols may not occur and, therefore, no ethnic
stratification can be found.
Specimens
The examination ofsputum for AFB remains the diagnos-
tic procedure most frequently requested by the physician.
When analyzing the ratio of the number of positive culture
results to the number of submitted specimens, we found a
striking difference between the ratio of clinically relevant
NTM isolates (I positive culture per 1.9 submitted speci-
mens) and the ratio of nonsignificant isolates (1 per 3.7).
This finding confirmed the value ofthe practice ofobtaining
at least three specimens for the diagnosis of NTM disease.
Large numbers of submitted specimens increase the chance
of finding nonsignificant isolates. This fact should always be
considered when positive culture results are being inter-
preted [46, 47, 49, 147].
It is important to emphasize that 44%ofall clinically signif-
icant isolates of NTM were positive for AFB in the direct
smear. This finding contrasts sharply with that for the group
of nonsignificant isolates where only 2%were smear positive.
It seems likely that these positive microscopic findings with
no clinical significance were caused by colonization of the
respiratory tract of these patients. All of the patients had
severe medical problems; six of eight had chronic lung dis-
ease, which is known to be a predisposing factor for coloniza-
tion.
In the immunocompetent host, the respiratory tract speci-
mens had the highest diagnostic yield. This finding can be
explained by differences of mode and site ofdisease. As was
shown before, the major site ofNTM infection in immuno-
competent hosts was the respiratory tract. In contrast, pa-
tients who have both AIDS and mycobacteriosis have mostly
disseminated disease, the route of infection possibly being
oral, as postulated by O'Brien [11].
We conclude that the direct smear, which is one ofthe first
clinical procedures performed with submitted specimens,
provides important evidence for diagnosis of AFB-related
diseases. TBC was found to be responsible for 424 of 447di-
rect smears positive for AFB. Fifteen smears positive for AFB
resulted from clinically significant NTM, and only eight
were caused by nonsignificant NTM.
Diagnostic and Prognostic Value of an NTM Isolate
When evaluating the diagnostic value and therefore the
clinical relevance ofa NTM isolate, we referred to the Yama-
moto criteria, which were established in 1967 [18]. Because
these criteria are not specific for a given NTM species, they
cannot be applied unconditionally. Basically, Yamamoto's
evaluation combines clinical and microbiological aspects
that support the clinical diagnosis of disease due to NTM.
For patients with extrapulmonary mycobacteriosis, the
Yamamoto criteria can be used with certain modifications.
We recommend that the following conditions be added to
the minor criteria: ( 1) two or more positive direct smears ofa
specimen considered not to have come from a normally ster-
ile area and resulting in a positive culture with moderate to
heavy growth; and (2) isolation of the same NTM species
from two or more specimens normally considered sterile
(e.g., blood, bone marrow, tissue, CSF). The identification
of mycobacteria in the routine laboratory has become more
efficient and faster [148, 149]. While the number ofTB cases
is decreasing, the number of NTM isolates is increasing.
These developments underscore the importance of proper
interpretation of positive results ofculture.
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